A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Summary

This is a Phase 1, open-label and multicenter study of SY-4798, a highly specific and potent inhibitor of FGFR4, in patients with advanced solid tumor. This study has two phases: dose-escalation phase and dose-expansion phase.

Timeline

Start

2021-04-15

Primary completion

2024-04-15

Completion

2024-04-15

Drugs

Indications